tagtociclib   Click here for help

GtoPdb Ligand ID: 11525

Synonyms: compound 19 [PMID: 35485642] | example 13 [WO2020157652] | PF-07104091 | PF07104091
Compound class: Synthetic organic
Comment: PF-07104091 is a novel, selective CDK2 inhibitor [2]. It is identical to the chemical structure for example 13 that is claimed in patent WO2020157652 [1], and it matches the structure for the INN tagtociclib (proposed INN list 129, August 2023).
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 3
Rotatable bonds 10
Topological polar surface area 123.16
Molecular weight 404.22
XLogP 1.73
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES COCc1nn(c(c1)C(=O)Nc1n[nH]c(c1)[C@H]1CC[C@H](C1)OC(=O)NC(C)C)C
Isomeric SMILES COCc1nn(c(c1)C(=O)Nc1n[nH]c(c1)[C@H]1CC[C@H](C1)OC(=O)NC(C)C)C
InChI InChI=1S/C19H28N6O4/c1-11(2)20-19(27)29-14-6-5-12(7-14)15-9-17(23-22-15)21-18(26)16-8-13(10-28-4)24-25(16)3/h8-9,11-12,14H,5-7,10H2,1-4H3,(H,20,27)(H2,21,22,23,26)/t12-,14+/m0/s1
No information available.
Summary of Clinical Use Click here for help
PF-07104091 is in clinical evaluation in advanced solid tumours.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04553133 PF-07104091 as a Single Agent and in Combination Therapy Phase 2 Interventional Pfizer
NCT05431153 A Study to Investigate the Effect of Tablet Formulation and Food on PF-07104091 in Healthy Participants Phase 1 Interventional Pfizer
NCT05262400 A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors Phase 1/Phase 2 Interventional Pfizer